Repeated neurofilament light chain measurements did not capture Riluzole therapeutic effect in amyotrophic lateral sclerosis patients.

However, when comparing sNfL1 and sNfL2 according to gender in ALS patients, although concentrations at sNfL2 were higher in both groups, this did not reach statistical significance. 3.2. sNfL concentrations increase with time in both ALS subgroups w/ and w/o Riluzole A total of 86 patients were already treated by Riluzole at inclusion in the study (w/Ril group), compared with 55 patients for whom Riluzole was started after inclusion (w/o Ril group).

also in 111,027 other papers